Offering patients eligible for Hep D medicine a chance – why not start now? | GileadPro

This website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in the United Kingdom. Adverse Events Reporting

The content of this webpage is promotional, and may contain information about Gilead's medicinal products. It is intended only for healthcare professionals and other relevant decision makers in the UK.

hcc-early-detection-banner

Offering patients eligible for Hepcludex (bulevirtide) a chance – why not start now?

Recorded: April 2025
Duration: 17:36

Dr Ahmed Elsharkawy discusses HDV and asks his audience to consider: why wait if you have a patient eligible for treatment with bulevirtide?

About the speaker

Ahmed Elsharkawy
Dr Ahmed Elsharkawy (1975–2026)

Ahmed Elsharkawy was a consultant hepatologist in Birmingham. He had a major interest in viral hepatitis and pioneered hepatitis C outreach clinics for marginalised populations in the city. He was a past Chairman of the British Viral hepatitis Group and led the BASL specialist interest group in hepatitis B. He was a strong advocate for the patient voice in viral hepatitis elimination and had been involved in trying to set up the first UK hepatitis B patient group.

hcc-early-detection-liver-connect

LIVER Connect Meetings

As requested by attendees, a selection of webinars from
2022 onwards are now available to watch on demand
You can also register here to attend the live webinars

Sign up now
Stay up to date

Receive email updates from Gilead, including promotional communications.

Register

UKI-HPX-0255 | June 2026